Current Headlines

  1. Curatis And Neupharma Announce Exclusive Licensing Agreement To Develop And Market Corticorelin (C-PTBE-01) For The Treatment Of Peritumoral Brain Edema In Japan 3/11/2026

    Curatis Holding AG and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan.

  2. Eledon Pharmaceuticals Announces Orphan Drug Designation Granted To Tegoprubart For The Prevention Of Allograft Rejection In Liver Transplantation 3/10/2026

     Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation.

  3. Mining The Dark Transcriptome: U Of T Engineering Researchers Create The First Potential Drug Molecules From Long Noncoding RNA 3/10/2026

    A team from U of T Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell — a new approach to drug discovery that has already yielded some promising anti-inflammatory molecules.

  4. AI Tool Streamlines Drug Synthesis 3/9/2026

    Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits and suddenly, a molecule makes a promising new medicine. Normally, creating better molecules consumes huge amounts of time and money.

  5. Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-OSA Trial Results 3/9/2026

    Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.

  6. GENFIT Receives FDA Orphan Drug Designation For NTZ For The Treatment Of ACLF 3/9/2026

    GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF).

  7. Harbour BioMed And Kelun-Biotech Announce NMPA Approval Of IND Application For HBM7575/SKB575 For The Treatment Of Atopic Dermatitis 3/9/2026

    Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of atopic dermatitis.

  8. Precision BioSciences Receives FDA Fast Track Designation For PBGENE-DMD And Announces Duchenne Muscular Dystrophy Investor Event 3/9/2026

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

  9. New Approach To Drug Development 3/6/2026

    In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to drug discovery. 

  10. GNTbm's Self-Developed Anti-Cancer New Drug GNTbm-38 Has Obtained IND Approval From The U.S. FDA For Phase I Clinical Trials 3/5/2026

    Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer immunotherapy, has received approval from the U.S. FDA for its IND application and will proceed with patient enrollment for a Phase I clinical trial in the United States.